1.TAZ WW Domain-Mediated Regulation of Gluconeogenesis and Tumorigenesis in Hepatocellular Carcinoma through Interaction with the Glucocorticoid Receptor
Hongxiang HUANG ; Jinhong CHEN ; Xingyu TAO ; Peiyuan ZHONG ; Yanqiu MENG ; Sujuan PENG ; Wanying LUO ; Zhiyong HE ; Shuai LUO ; Xie ZHU ; Zhihui LU ; Li CHEN ; Yangyang LIU
Endocrinology and Metabolism 2026;41(2):267-287
Background:
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, characterized by poor prognosis due to its high proliferative and invasive potential. Tumor metabolic reprogramming, particularly involving glucose metabolism, is essential for tumor survival. This study investigates the role of the Hippo pathway effector transcriptional co-activator with PDZ-binding motif (TAZ) in regulating gluconeogenesis and promoting tumorigenesis in HCC.
Methods:
TAZ expression in HCC was analyzed using The Cancer Genome Atlas data and validated in clinical samples and cell lines. TAZ was overexpressed or silenced in HCC cell lines to evaluate its effects on cell proliferation, apoptosis, migration, and invasion. The expression and prognostic relevance of the gluconeogenesis-related genes phosphoenolpyruvate carboxykinase 1 (PCK1) and glucose-6-phosphatase (G6PC) were examined, along with their correlation with TAZ expression. Tumor growth was assessed in nude mice. Interactions between TAZ and the glucocorticoid receptor (GR) were investigated using co-immunoprecipitation, immunofluorescence, and chromatin immunoprecipitation assays.
Results:
TAZ was significantly upregulated in HCC tissues and cell lines. TAZ overexpression enhanced proliferation, reduced apoptosis, and promoted migration and invasion. In contrast, PCK1 and G6PC were downregulated in HCC and showed a negative correlation with TAZ expression.
Conclusion
TAZ modulates gluconeogenesis and accelerates tumor growth, whereas its knockdown attenuates tumor progression. TAZ interacts with GR, suppressing its transcriptional activity on gluconeogenic gene promoters.
2.Evaluation on the Traditional Chinese Medicine Service Capacity in Secondary and above General Hospitals in Jiang-su Province
Chang'e ZHU ; Lülin ZHOU ; Peiyuan CAI ; Baoxiang SONG
Chinese Health Economics 2025;44(5):17-22
Objective:To systematically evaluate the service capacity of Traditional Chinese Medicine(TCM)in secondary and above general hospitals in Jiangsu Province and to uncover differences in service capacity across economic types,hospital grades,and re-gions.Methods:The entropy weight method was employed to conduct a comprehensive evaluation of the TCM service capacity of 579 sec-ondary and above general hospitals in Jiangsu Province.Additionally,T-tests were used to compare these four dimensions of human re-sources,financial resources,material resources,and resource utilization efficiency across different types of hospitals.Results:The TCM service capacities in Nanjing,Suzhou,and Wuxi ranked among the highest in Jiangsu,with comprehensive scores of 0.810,0.676,and 0.426,respectively.In contrast,Taizhou and Zhenjiang exhibited relatively weaker service capacities,with scores of only 0.067 and 0.049.The service levels in other regions were moderate.Furthermore,the results of T-tests and entropy weight method indicated significant differences(P<0.05)in TCM service capacity across hospital grades and economic types for most dimensions,while regional differences were not statistically significant(P>0.05).Conclusion:There is significant imbalance in the TCM ser-vice capacity across Jiangsu Province.Economically developed cities(e.g.,Nanjing,Suzhou,and Wuxi)demonstrate strong service capacities,while certain regions(e.g.,Taizhou and Zhenjiang)are relatively weak.The service capacity of public and tertiary hospi-tals is significantly higher than that of private and secondary hospitals;however,regional differences are not significant.Future efforts should focus on policy support for regions with lower resource utilization efficiency and weaker hospitals,aiming to promote a more bal-anced and efficient development of TCM services to better meet the growing demand for TCM across different areas and populations.
3.Evaluation on the Traditional Chinese Medicine Service Capacity in Secondary and above General Hospitals in Jiang-su Province
Chang'e ZHU ; Lülin ZHOU ; Peiyuan CAI ; Baoxiang SONG
Chinese Health Economics 2025;44(5):17-22
Objective:To systematically evaluate the service capacity of Traditional Chinese Medicine(TCM)in secondary and above general hospitals in Jiangsu Province and to uncover differences in service capacity across economic types,hospital grades,and re-gions.Methods:The entropy weight method was employed to conduct a comprehensive evaluation of the TCM service capacity of 579 sec-ondary and above general hospitals in Jiangsu Province.Additionally,T-tests were used to compare these four dimensions of human re-sources,financial resources,material resources,and resource utilization efficiency across different types of hospitals.Results:The TCM service capacities in Nanjing,Suzhou,and Wuxi ranked among the highest in Jiangsu,with comprehensive scores of 0.810,0.676,and 0.426,respectively.In contrast,Taizhou and Zhenjiang exhibited relatively weaker service capacities,with scores of only 0.067 and 0.049.The service levels in other regions were moderate.Furthermore,the results of T-tests and entropy weight method indicated significant differences(P<0.05)in TCM service capacity across hospital grades and economic types for most dimensions,while regional differences were not statistically significant(P>0.05).Conclusion:There is significant imbalance in the TCM ser-vice capacity across Jiangsu Province.Economically developed cities(e.g.,Nanjing,Suzhou,and Wuxi)demonstrate strong service capacities,while certain regions(e.g.,Taizhou and Zhenjiang)are relatively weak.The service capacity of public and tertiary hospi-tals is significantly higher than that of private and secondary hospitals;however,regional differences are not significant.Future efforts should focus on policy support for regions with lower resource utilization efficiency and weaker hospitals,aiming to promote a more bal-anced and efficient development of TCM services to better meet the growing demand for TCM across different areas and populations.
4.Current research status on the inhibition of platelet activation by blood-activating and stasis-resolving traditional Chinese medicine
Wenqiu FENG ; Ying HE ; Peiyuan ZHU
Chinese Journal of Blood Transfusion 2025;38(11):1602-1610
Platelet activation plays a crucial role in the pathogenesis of cardiovascular and cerebrovascular diseases and the safety of platelet transfusion. Blood-activating and stasis-resolving Chinese herbs, known for improving blood circulation and eliminating blood stasis, can be classified into four categories: blood-activating and pain-relieving herbs, blood-activating and menstruation-regulating herbs, blood-activating and wound-healing herbs, and blood-breaking and mass-eliminating herbs. Modern research has revealed that these herbs exert antiplatelet activation effects through multiple molecular mechanisms. Key mechanisms include regulating the arachidonic acid metabolic pathway, inhibiting platelet membrane receptor function, influencing intracellular signal transduction, and modulating platelet-vascular endothelial interactions. Compared with conventional antiplatelet drugs, blood-activating and stasis-resolving Chinese herbs offer the advantage of multi-pathway synergistic effects and demonstrate potential value in prolonging platelet storage. This article systematically elaborates on the active monomers and mechanisms of these four categories of Chinese herbs in inhibiting platelet activation, summarizing their multi-target and multi-pathway characteristics, aiming to provide a theoretical basis for the clinical application of these herbs in suppressing platelet activation.
5.Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients (version 2024)
Yao LU ; Yang LI ; Leiying ZHANG ; Hao TANG ; Huidan JING ; Yaoli WANG ; Xiangzhi JIA ; Li BA ; Maohong BIAN ; Dan CAI ; Hui CAI ; Xiaohong CAI ; Zhanshan ZHA ; Bingyu CHEN ; Daqing CHEN ; Feng CHEN ; Guoan CHEN ; Haiming CHEN ; Jing CHEN ; Min CHEN ; Qing CHEN ; Shu CHEN ; Xi CHEN ; Jinfeng CHENG ; Xiaoling CHU ; Hongwang CUI ; Xin CUI ; Zhen DA ; Ying DAI ; Surong DENG ; Weiqun DONG ; Weimin FAN ; Ke FENG ; Danhui FU ; Yongshui FU ; Qi FU ; Xuemei FU ; Jia GAN ; Xinyu GAN ; Wei GAO ; Huaizheng GONG ; Rong GUI ; Geng GUO ; Ning HAN ; Yiwen HAO ; Wubing HE ; Qiang HONG ; Ruiqin HOU ; Wei HOU ; Jie HU ; Peiyang HU ; Xi HU ; Xiaoyu HU ; Guangbin HUANG ; Jie HUANG ; Xiangyan HUANG ; Yuanshuai HUANG ; Shouyong HUN ; Xuebing JIANG ; Ping JIN ; Dong LAI ; Aiping LE ; Hongmei LI ; Bijuan LI ; Cuiying LI ; Daihong LI ; Haihong LI ; He LI ; Hui LI ; Jianping LI ; Ning LI ; Xiying LI ; Xiangmin LI ; Xiaofei LI ; Xiaojuan LI ; Zhiqiang LI ; Zhongjun LI ; Zunyan LI ; Huaqin LIANG ; Xiaohua LIANG ; Dongfa LIAO ; Qun LIAO ; Yan LIAO ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Peixian LIU ; Tiemei LIU ; Xiaoxin LIU ; Zhiwei LIU ; Zhongdi LIU ; Hua LU ; Jianfeng LUAN ; Jianjun LUO ; Qun LUO ; Dingfeng LYU ; Qi LYU ; Xianping LYU ; Aijun MA ; Liqiang MA ; Shuxuan MA ; Xainjun MA ; Xiaogang MA ; Xiaoli MA ; Guoqing MAO ; Shijie MU ; Shaolin NIE ; Shujuan OUYANG ; Xilin OUYANG ; Chunqiu PAN ; Jian PAN ; Xiaohua PAN ; Lei PENG ; Tao PENG ; Baohua QIAN ; Shu QIAO ; Li QIN ; Ying REN ; Zhaoqi REN ; Ruiming RONG ; Changshan SU ; Mingwei SUN ; Wenwu SUN ; Zhenwei SUN ; Haiping TANG ; Xiaofeng TANG ; Changjiu TANG ; Cuihua TAO ; Zhibin TIAN ; Juan WANG ; Baoyan WANG ; Chunyan WANG ; Gefei WANG ; Haiyan WANG ; Hongjie WANG ; Peng WANG ; Pengli WANG ; Qiushi WANG ; Xiaoning WANG ; Xinhua WANG ; Xuefeng WANG ; Yong WANG ; Yongjun WANG ; Yuanjie WANG ; Zhihua WANG ; Shaojun WEI ; Yaming WEI ; Jianbo WEN ; Jun WEN ; Jiang WU ; Jufeng WU ; Aijun XIA ; Fei XIA ; Rong XIA ; Jue XIE ; Yanchao XING ; Yan XIONG ; Feng XU ; Yongzhu XU ; Yongan XU ; Yonghe YAN ; Beizhan YAN ; Jiang YANG ; Jiangcun YANG ; Jun YANG ; Xinwen YANG ; Yongyi YANG ; Chunyan YAO ; Mingliang YE ; Changlin YIN ; Ming YIN ; Wen YIN ; Lianling YU ; Shuhong YU ; Zebo YU ; Yigang YU ; Anyong YU ; Hong YUAN ; Yi YUAN ; Chan ZHANG ; Jinjun ZHANG ; Jun ZHANG ; Kai ZHANG ; Leibing ZHANG ; Quan ZHANG ; Rongjiang ZHANG ; Sanming ZHANG ; Shengji ZHANG ; Shuo ZHANG ; Wei ZHANG ; Weidong ZHANG ; Xi ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Xiaojun ZHANG ; Guoqing ZHAO ; Jianpeng ZHAO ; Shuming ZHAO ; Beibei ZHENG ; Shangen ZHENG ; Huayou ZHOU ; Jicheng ZHOU ; Lihong ZHOU ; Mou ZHOU ; Xiaoyu ZHOU ; Xuelian ZHOU ; Yuan ZHOU ; Zheng ZHOU ; Zuhuang ZHOU ; Haiyan ZHU ; Peiyuan ZHU ; Changju ZHU ; Lili ZHU ; Zhengguo WANG ; Jianxin JIANG ; Deqing WANG ; Jiongcai LAN ; Quanli WANG ; Yang YU ; Lianyang ZHANG ; Aiqing WEN
Chinese Journal of Trauma 2024;40(10):865-881
Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.
6.Recent progress of organoids and organ-on-a-chip technology in Alzheimer′s disease
Menghan ZHOU ; Peiyuan ZHU ; Leqi CAO ; Wenying SHI ; Fangyuan QIAN
Chinese Journal of Neurology 2024;57(7):789-794
Alzheimer′s disease (AD) is a neurodegenerative disorder. In the past few decades, the exact mechanisms underlying the onset of the disease have remained unclear, and treatment options are still lacking. Due to the inability of two-dimensional cell and animal models to fully simulate the pathogenesis of AD, there have been shortcomings in clinical trials of new drugs. The development of organoids and organ-on-a-chip technologies has improved the dilemma of AD research, providing reliable in vitro research models for studying pathogenic mechanisms and drug screening. This article elaborates on the applications and progress of organoids and organ-on-a-chip in AD modeling, pathogenesis, and drug development, and discusses the current limitations of organoids and organ-on-a-chip and their future perspectives.
7.Research progress of brain organoid technology in microcephaly
Leqi CAO ; Wenying SHI ; Menghan ZHOU ; Peiyuan ZHU ; Xiyu WANG ; Fangyuan QIAN
Chinese Journal of Perinatal Medicine 2024;27(10):871-875
Microcephaly is a common pediatric neurodevelopmental disorder with complex etiology. In recent years, with the development of brain organoid technology, there has been rapid progress in understanding the pathogenesis and treatment strategies of microcephaly using this technology. This article elucidates the advantages of brain organoids over traditional experimental models, reviews the research progress of brain organoid technology in disease modeling and drug screening for various causes of microcephaly, and discusses the limitations and future prospects of brain organoids.
8.Research on diagnostic value of thrombin-antithrombin complex,thrombomodulin and tissue plasminogen activator-inhibitor complex for COVID-19
Fengwei GAO ; Lin ZHOU ; Xiaobao SHAO ; Hua WANG ; Yuan YANG ; Xin CHEN ; Yi LIU ; Peiyuan ZHU
Chinese Journal of Clinical Laboratory Science 2024;42(10):748-753
Objective To retrospectively analyze the diagnostic value of thrombin-antithrombin complex(TAT),thrombomodulin(TM),and tissue plasminogen activator-inhibitor complex(t-PAIC)in severe cases of corona virus disease 2019(COVID-19).Methods A cohort of 79 patients clinically diagnosed with COVID-19 was retrospectively assembled and categorized into two groups based on disease severity:non-severe(n=51)and severe(n=28).In this study the differences of coagulation function and inflamma-tory marker levels between the two groups were compared.The correlations of TAT,TM and t-PAIC with other biomarkers were investi-gated.The diagnostic values of all the markers for severe COVID-19 were assessed.Results The patients of severe COVID-19 exhibi-ted significantly higher levels of TAT,TM,and t-PAIC compared to those of non-severe group(P<0.001).The levels of TAT,TM and t-PAIC showed notable positive correlation with other biomarkers.TAT demonstrated the strongest positive correlation with the level of D-dimer(r=0.786,P<0.001).Binary logistic regression analysis identified TAT(OR=1.346,P<0.05)and t-PAIC(OR=1.128,P<0.05)were independent risk factors in term of severe COVID-19.The combined ROC curve for TAT,TM and t-PAIC revealed high diagnostic efficacy in severe cases with the area under the curve(AUCROC)were 0.918,and the sensitivity and specificity were of 75%and 94.1%,respectively.Conclusion The results of combined measurement of TAT,TM and t-PAIC effectively demonstrates its diagnostic value in identifying severity and stratification of COVID-19 cases and may have important clinical significance for assessment of the severity and prediction of the prognosis.
9.Inhibitory effect of Salidroside on the interaction between human platelets and breast cancer MDA-MB-468 cells
Yihan SHAO ; Xiaobao SHAO ; Weina ZHU ; Xin CHEN ; Lin ZHOU ; Peiyuan ZHU
Chinese Journal of Blood Transfusion 2024;37(7):754-760
Objective To study the effect of Salidroside(Sal)on platelet activation and aggregation and the interaction between human platelets and MDA-MB-468 cells of breast cancer.Methods Human platelets were collected,platelet sus-pension was prepared,and platelets were treated with different concentrations of Sal.The effects of Sal on platelet activation and aggregation were detected by thromboelastogram(TEG)and flow cytometry.Breast cancer MDA-MB-468 cells were cul-tured in vitro,and human platelets were treated with different concentrations of Sal,and then activated by thrombin.The effects of Sal on the interaction between platelets and MDA-MB-468 cells were analyzed by adhesion test and scratch test.Re-sults TEG detection:The ADP inhibition rate in the blank control group was(10.97±12.69)%,and the ADP inhibition rate in all Sal intervention groups was higher than that in the blank control group(P<0.05).The AA inhibition rate was(8.11±7.84)%in the control group and(25.96±15.18)%in the 5 μmol/L Sal intervention group,and the difference was statistically significant(P<0.05).Flow cytometry:The expression of CD62P on platelet surface in 40 and 60 μmol/L Sal groups was(56.5±0.17)%and(65.50±0.36)%,respectively,and the difference was statistically significant compared with the positive control group(76.53±0.49)%(P<0.05).The percentages of PAC-1 expression on platelet surface in 40 and 60 μmol/L Sal groups were(62.20±0.10)%and(58.47±0.15)%,and the difference was statistically significant com-pared with the positive control group(72.10±0.20)%(P<0.05).Adhesion experiment:Platelets can have adhesion with MDA-MB-468 cells,and activated platelets have stronger adhesion ability.The adhesion rate in the Sal group was signifi-cantly lower than that in the positive control group,and was negatively correlated with the concentration of Sal.Scratch test:The cell mobility at 24 h in the positive control group was(12.71±0.70)%,and the cell mobility in each Sal treatment group was(4.51±0.44)%,(3.85±0.11)%,(5.37±0.36)%,(4.15±0.13)%and(3.55±0.38)%,respectively,showing significant decrease compared with the positive control group(P<0.05).After 48 h of Sal treatment,the cell mobility of 10,20,40 and 60μmol/L Sal groups decreased,and there was a statistical difference compared with the positive control group(P<0.05).Conclusion Sal can inhibit the adhesion between activated platelets mediated by thrombin and MDA-MB-468 cells and the migration of MDA-MB-468 cells.
10.Cost-effectiveness of pharmaceutical smoking cessation intervention in China primary cancer prevention
Peiyuan SUN ; Yuting XIE ; Ranran QIE ; Huang HUANG ; Zhuolun HU ; Mengyao WU ; Qi YAN ; Cairong ZHU ; Jufang SHI ; Kaiyong ZOU ; Yawei ZHANG
Chinese Journal of Oncology 2024;46(1):66-75
Objectives:To evaluate the cost-effectiveness of typical pharmaceutical smoking cessation intervention strategies in China in the context of primary cancer prevention.Methods:Markov cohort simulation models were established to simulate the burden of 12 smoking caused cancer, including lung cancer, oral cancer, nasopharyngeal cancer, laryngeal cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, kidney cancer, bladder cancer, cervical cancer, and acute myeloid leukemia. Taking incremental cost effectiveness ratio (ICER) as the main indicator, the model sets one year as the cycling period for 50 periods and simulates the cohort of 10 000 thirty-five-year-old current smokers with various smoking cessation strategies. To ensure the robustness of conclusion, univariate sensitivity analysis, probability sensitivity analysis, and age-group sensitivity analysis were conducted.Results:The results showed that varenicline intervention was the most cost-effective intervention. Compared to the next most effective option, incremental cost of each additional quality-adjusted life year is 11 140.28 yuan, which is below the threshold of willingness to pay (1 year GDP per capita). The value of ICER increased as the increasing age group of adopting intervention, but neither exceeded the threshold of willingness to pay. One-way sensitivity analysis showed that the value of discount rate, the hazard ratio and cost of intervention strategy had a greater impact on the result of ICER.Conclusion:In China, the use of varenicline to quit smoking is highly cost effective in the context of cancer primary prevention, especially for younger smokers.

Result Analysis
Print
Save
E-mail